文献速递心力衰竭与心肌病

杜氏肌营养不良症心力衰竭的当前管理策略

A current approach to heart failure in Duchenne muscular dystrophy.
PubMed 文献 · Heart · 2017-07-01

本文综述杜氏肌营养不良症(DMD)患者心力衰竭的诊疗挑战与现状。DMD为遗传性进行性神经肌肉疾病,终末期心衰已成为该人群主要死因;心肌病早期诊断困难,因存在较长亚临床心室功能障碍期且心血管症状评估困难。超声心动图和心电图用于筛查,心脏磁共振钆延迟强化有望检测早期心脏受累;早期诊断可及时启动心脏保护治疗以缓解心衰症状并延缓心肌重构。

要点

  • DMD终末期心衰已成主要死因,早期心肌病诊断困难。
  • 超声心动图和心电图常规筛查,心脏磁共振钆延迟强化可早期检测。
  • 早期诊断可及时启动心脏保护药物,延缓心肌重构。

核心结论

  • DMD患者终末期心衰日益成为主要死因,早期诊断心肌病对及时启动心脏保护治疗至关重要。

研究设计与样本

  • 本文为综述,聚焦DMD患者心力衰竭的诊疗挑战与可用选择。

主要发现

  • DMD为遗传性进行性神经肌肉疾病,伴长期肌肉退化并显著影响肺和心脏功能。
  • 心肌病存在较长亚临床心室功能障碍期,且患者多在青春期早期丧失行走能力,心血管症状评估困难。
  • 超声心动图和心电图是筛查心血管异常的标准工具,但不总能检测早期临床无症状阶段。
  • 心脏磁共振钆延迟强化正成为检测DMD早期心脏受累的有前景方法。

关键数值与推荐

  • 早期发现心功能不全可启用皮质类固醇、β受体阻滞剂、ACE抑制剂、抗盐皮质激素利尿剂及新型药物和手术方案。

临床怎么用

  • 对DMD患者应利用超声心动图和心电图筛查,并考虑心脏磁共振钆延迟强化以早期发现心脏受累。
  • 早期诊断后及时启动心脏保护药物,以缓解心衰症状并延缓心肌重构。
  • 在多模式多学科护理中综合运用药物和新型手术方案管理心衰。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Duchenne muscular dystrophy (DMD) is a genetic, progressive neuromuscular condition that is marked by the long-term muscle deterioration with significant implications of pulmonary and cardiac dysfunction. As such, end-stage heart failure (HF) in DMD is increasingly becoming the main cause of death in this population. The early detection of cardiomyopathy is often challenging, due to a long subclinical phase of ventricular dysfunction and difficulties in assessment of cardiovascular symptomatology in these patients who usually loose ambulation during the early adolescence. However, an early diagnosis of cardiovascular disease in patients with DMD is decisive since it allows a timely initiation of cardioprotective therapies that can mitigate HF symptoms and delay detrimental heart muscle remodelling. Echocardiography and ECG are standardly used for screening and detection of cardiovascular abnormalities in these patients, although these tools are not always adequate to detect an early, clinically asymptomatic phases of disease progression. In this regard, cardiovascular magnetic resonance (CMR) with late gadolinium enhancement is emerging as a promising method for the detection of early cardiac involvement in patients with DMD. The early detection of cardiac dysfunction allows the therapeutic institution of various classes of drugs such as corticosteroids, beta-blockers, ACE inhibitors, antimineralocorticoid diuretics and novel pharmacological and surgical solutions in the multimodal and multidisciplinary care for this group of patients. This review will focus on these challenges and available options for HF in patients with DMD.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. D'Amario D, Amodeo A, Adorisio R, et al. A current approach to heart failure in Duchenne muscular dystrophy. Heart. 2017. PMID: 28668906. doi:10.1136/heartjnl-2017-311269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。